Table 1. Characteristics at Diagnosis... | American Society of Hematology

Table 1.

Characteristics at Diagnosis and at ABMT

Patients	Characteristics at Diagnosis									Characteristics at ABMT
Patients	Age/ Sex	Disease Phase	Breakpoint	Hb g/dL	WBC ×10⁹/L	PLTS ×10⁹/L	Liver Size	Spleen Size	Therapy	Duration 1 CP (mo)	Disease Phase	% BM Blast Cells
1	30/M	CP	B2A2	13	130	300	Not palpable	Not palpable	IFN-α/HU	3	AP	10
2	20/M	CP	B3A2	12	380	500	Not palpable	Enlarged	IFN-α	22	AP	7
3	39/M	CP	B3A2	14	64	294	Not palpable	Not palpable	IFN-α	26^-150	2^nd CP	—
4	21/F	CP	B2A2	14	31	800	Enlarged	Enlarged	IFN-α	18	AP	10
5	41/F	CP	B3A2	10	127	900	Not palpable	Massive	IFN-α	35	AP	15
6	29/F	CP	B2A2	7	300	500	Enlarged	Enlarged	IFN-α	21	AP	10
7	47/M	CP	B2A2	13	130	300	Enlarged	Not palpable	IFN-α	33	AP	8
8	39/M	CP	B2A2	12	17	260	Not palpable	Not palpable	IFN-α	52	AP	15

Patients	Characteristics at Diagnosis									Characteristics at ABMT
Patients	Age/ Sex	Disease Phase	Breakpoint	Hb g/dL	WBC ×10⁹/L	PLTS ×10⁹/L	Liver Size	Spleen Size	Therapy	Duration 1 CP (mo)	Disease Phase	% BM Blast Cells
1	30/M	CP	B2A2	13	130	300	Not palpable	Not palpable	IFN-α/HU	3	AP	10
2	20/M	CP	B3A2	12	380	500	Not palpable	Enlarged	IFN-α	22	AP	7
3	39/M	CP	B3A2	14	64	294	Not palpable	Not palpable	IFN-α	26^-150	2^nd CP	—
4	21/F	CP	B2A2	14	31	800	Enlarged	Enlarged	IFN-α	18	AP	10
5	41/F	CP	B3A2	10	127	900	Not palpable	Massive	IFN-α	35	AP	15
6	29/F	CP	B2A2	7	300	500	Enlarged	Enlarged	IFN-α	21	AP	10
7	47/M	CP	B2A2	13	130	300	Enlarged	Not palpable	IFN-α	33	AP	8
8	39/M	CP	B2A2	12	17	260	Not palpable	Not palpable	IFN-α	52	AP	15

Abbreviations: Hb, hemoglobin; WBC, white blood cell; PLTS, platelets; CP, chronic phase; AP, accelerated phase.

This patient developed lymphoid blast crisis with extramedullary localization and was treated with high-dose ARA-C + etoposide + adryamycin.